Table 3.
Differences in rates of decline in eGFR (mL·min-1·1.73 m-2·yr-1, mean ± standard error) between genders and between groups
| Health group (n = 4569) | Risk group (n = 7434) | CKD group (n = 1573) | ||||
|---|---|---|---|---|---|---|
| Male (n = 1311) |
Female (n = 3258) |
Male (n = 3338) |
Female (n = 4096) |
Male (n = 676) |
Female (n = 897) |
|
| Unadjusted rates of decline in eGFR | 0.51 ± 0.04* | 0.75 ± 0.03 | 0.53 ± 0.02* | 0.67 ± 0.02 | 0.89 ± 0.06 | 0.88 ± 0.06 |
| Covariate-adjusted rates of decline in eGFR† | 0.52 ± 0.04* | 0.75 ± 0.04 | 0.62 ± 0.03* | 0.71 ± 0.03 | 0.94 ± 0.06 | 0.90 ± 0.08 |
| Covariate-adjusted rates of decline in eGFR† (referenced to healthy group) | - | - | 0.10 ± 0.05& | -0.03 ± 0.04 | 0.44 ± 0.06& | 0.15 ± 0.06& |
| Gender difference in covariate-adjusted rates of decline in eGFR† (referenced to healthy group) | - | 0.10 ± 0.06 | 0.29 ± 0.09# | |||
*: Compared to women in the same health status group, p < 0.05
&: Compared to healthy group in the same gender, p < 0.05
#: p < 0.05
†: Controlled for age, blood pressure, fasting glucose level, serum lipid level, education level, and smoking frequency